Guest article by Catherine Hartmann, EPHA’s Scientific Advisor on Brussels Advocacy and former Executive Director of the European Blood Alliance (EBA) Next week, EU decision-makers will make choices regarding Substances of Human Origin (SoHO) that will tie the...
EU’s founding father Jean Monnet is widely quoted for saying that “Europe will be forged in crisis and will be the sum of the solutions adopted for those crises”. The regulation of medicines across the Union seems to have followed this logic. Developed in 1965,...
Previous to the publication of the EC proposal to review the EU pharmaceutical legislation, EPHA had called for more transparency of the research and development (R&D) costs for pharmaceutical products. Without clear knowledge of pharmaceutical R&D costs, it...
By Charlotte Roffiaen, France Assos Santé With the COVID-19 pandemic and the multiplication of antibiotic supply disruptions, the fight against medicine shortages has become one of the first priorities of the EU and its Member States. This is perfectly reflected in...
By Dr Ward Rommel, Chair, Access to Medicines Task Force of Association of European Cancer Leagues (ECL) – @CancerLeagues & @WardRommel | #LetsTalkAccess In Europe, around 2.7 million people are diagnosed with cancer every year – and this number is set to...